25 April 2024 in Nature Immunology
31 March 2025 in PLOS Genetics
Prostate cancer (PC) is the most frequently diagnosed malignancy among men and contributes significantly to cancer-related mortality. While recent advances in in vitro PC modeling systems have been made, there remains a lack of robust preclinical models that faithfully recapitulate the genetic and phenotypic characteristics across various PC subtypes—from localized PC (LPC) to castration-resistant PC (CRPC)—along with associated stromal cells. Here, we established human PC assembloids from LPC and CRPC tissues by reconstituting tumor organoids with corresponding cancer-associated fibroblasts (CAFs), thereby incorporating aspects of the tumor microenvironment (TME). Established PC organoids exhibited high concordance in genomic landscape with parental tumors, and the tumor assembloids showed a higher degree of phenotypic similarity to parental tumors compared to tumor organoids without CAFs. PC assembloids displayed increased proliferation and reduced sensitivity to anti-cancer treatments, indicating that PC assembloids are potent tools for understanding PC biology, investigating the interaction between tumor and CAFs, and identifying personalized therapeutic targets.
25 November 2025 in Nature Communications
Despite recent advances, current brain organoid technologies face ongoing challenges in managing heterogeneity and representing the diverse structure and cell types of the human brain. Here, we develop a module-based cellular reconstitution technology to sequentially build uniform cortical assembloids with mature cortical structures and functional connectivity. The uniformity and maturity of the cortical assembloids are achieved by creating single-rosette-based organoids at the early stage, whose sizes were big and consistent with the treatment of Wnt and Hedgehog agonists, followed by spatial reconstitution with the Reelin-expressing neuronal layer and non-neuronal glial cells. The resulting single-rosette-based cortical assembloids are highly uniform and reproducible without significant batch effects, solving major heterogeneity issues caused by difficulties in controlling the number and size of rosettes in conventional multi-rosette organoids. Furthermore, these cortical assembloids structurally and functionally recapitulate the physiology of the human brain, including the six-layered cortical structure, functional connectivity, and dynamic cellular interplay between neurons and glial cells. Our study thus provides an innovative preclinical model to study a range of neurological disorders, understanding the pathogenesis of which requires an organoid system capable of representing the dynamic cellular interactions and the maturity of the human brain.
26 September 2025 in Genomics, Proteomics & Bioinformatics
Diverse molecular networks have been extensively studied to discover therapeutic targets and repurpose approved drugs. However, it is necessary to select a suitable network since the performance of network medicine relies heavily on the completeness and characteristics of the selected network. Although a network using gene essentiality in cancer cells could be an effective platform for identifying anticancer targets, efforts to apply these networks to therapeutic applications have been limited. We constructed a phenotype-level network using co-essentiality relationships among genes from CRISPR screens across 769 cancer cell lines to discover therapeutic targets for diverse cancer types. By leveraging cancer driver genes and network propagation, we found that the co-essentiality network better prioritized anticancer targets and biomarkers and predicted more precise drug responses in cancer cells than other molecular networks. The co-essentiality network outperformed conventional molecular networks in drug repurposing and was validated in silico by clinical trial records. Notably, the co-essentiality network identified 30 repurposed drugs that the other networks have not yet covered, and we showcased three approved drugs repurposed for lung adenocarcinoma (atovaquone, eflornithine, and teriflunomide). Our study provides a novel network for precision oncology to improve the identification of therapeutic targets in specific cancers.
28 October 2026 in Nature
Dynamic interactions between tumours and their microenvironment are crucial for cancer progression and therapeutic outcomes 1,2 . However, our understanding of these relationships remains limited by the constrained capacity of current human model systems to manipulate diverse cellular components and to interrogate complex tumour–stroma crosstalk. Here we generated combinatorial, mix-and-match tumour assembloids by conditionally reconstituting multiple components of human renal cell carcinoma, including cancer cells, cancer-associated fibroblasts (CAFs) and tumour-infiltrating immune cells. Using genetically engineered renal cell carcinoma assembloids with humanized mouse models, we uncovered mechanisms by which CAFs coordinate interactions between tumour cells and CD8 + T cells to maintain non-cell-autonomous CD8 + T cell stemness and drive responsiveness to anti-PD-1 therapy. These interactions operate through a tumour–CAF–T cell signalling axis in which tumour-derived WNT induces CAF expression of activin A, which enhances CD8 + T cell stemness and sensitivity to PD-1 blockade. In non-responders, we also identified a subset of WNT-unresponsive CAFs that do not produce activin A, which leads to impaired CD8 + T cell stemness and resistance to therapy. Together, these findings establish a tumour–CAF–T cell axis as a key determinant of heterogeneous responses to immune checkpoint inhibitors. Moreover, tumour assembloids provide a versatile platform for mechanistic dissection of the tumour microenvironment and evaluation of personalized immunotherapy strategies.
22 December 2024 in bioRxiv
Diverse molecular networks have been extensively studied to discover therapeutic targets and repurpose approved drugs. However, it is necessary to select a suitable network since the performance of network medicine relies heavily on the completeness and characteristics of the selected network. Although a network using gene essentiality from cancer cells could be an effective platform for identifying anticancer targets, efforts to apply these networks in therapeutic applications have been limited. We constructed a phenotype-level network using the co-essentiality relationship between genes in CRISPR screens across 769 cancer cells to discover therapeutic targets for diverse cancer types. Leveraging cancer driver genes and network propagation on the networks, we found that the co-essentiality network better prioritized anticancer targets and biomarkers and predicted more precise drug responses in cancer cells than other molecular networks. The co-essentiality network outperformed conventional molecular networks in drug repurposing, which were validated in silico by clinical trial records. Notably, the co-essentiality network provided 37 repurposed drugs that the other networks have yet to cover, and we showcased three approved drugs repurposed for lung adenocarcinoma (Pioglitazone hydrochloride, Atovaquone, and Eflornithine). Our study provides a novel network for precision oncology to improve the identification of therapeutic targets in specific cancers.